CorMedix Inc - רווח למניה אחת ב-12 החודשים האחרונים CRMD

The annual EPS (TTM) growth rate demonstrates the resilience of CorMedix Inc. (CRMD), with the metric reaching -64.20. A stable FCF stream is provided by Defencath sales contracts in dialysis centers. The application of algorithms automates the synthesis of new agents, although tests remain under the control of scientists. An efficient transition to the commercialization of the approved product has strengthened shareholder confidence in management.
cormedix.com - פילוחים אנליטיים ומדדי מפתח (CRMD)

This indicator measures the dynamics of the rolling twelve-month earnings per share, neutralizing timing gaps between quarterly reports to assess margin resilience against external shocks. By analyzing the annual growth rate of EPS TTM, an investor can evaluate the scaling potential of CorMedix Inc. (CRMD), where high profitability of antiseptics coupled with low production costs should translate into accelerated earnings.